RxDoctor Payments Data

Alexandra Ingram

Family · Miami, FLNPI 1730843194

Payments from drug & device makers

$10,021in general payments, 2019–2025

Across 77 payments — averaging $130.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Medtronic$2K
  • Boston Scientific$2K
  • Abbott$906
  • Acadia Pharmaceuticals Inc$377
  • Neurocrine Biosciences, Inc.$183
  • plus $549 from 9 others

What the payments were for

  • Consulting fees$2,58226%
  • Travel & lodging$4,40244%
  • Food & beverage$2,93829%
  • Education$981%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,021 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$51,793
Medicare patients
319
Services billed
594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate190$1,163,478
IngrezzaValbenazine Tosylate66$546,698
GocovriAmantadine Hcl125$499,912
RytaryCarbidopa/Levodopa325$368,282
InbrijaLevodopa70$235,952
BotoxOnabotulinumtoxina127$157,851
Droxidopa37$107,822
NeuproRotigotine90$101,396
Austedo XrDeutetrabenazine15$97,107
OngentysOpicapone85$67,192
NourianzIstradefylline24$61,796
Carbidopa-LevodopaCarbidopa/Levodopa1,243$34,877
Nurtec OdtRimegepant Sulfate17$33,033
CrexontCarbidopa/Levodopa35$29,146
MyoblocRimabotulinumtoxinb30$26,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$377$1,163,478190 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$183$613,889151 claims
MDD US Operations, LLCGocovri$71$499,912125 claims
Amneal Pharmaceuticals LLCRytary, Crexont$135$397,428360 claims
AbbVieBotox, Linzess$3,822$172,182144 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$63$97,10715 claims
Kyowa Kirin, Inc.Nourianz$46$61,79624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →